JP5565906B2 - スカベンジャー受容体−ａを抑制する方法および抗原への免疫応答を増大する方法 - Google Patents

スカベンジャー受容体−ａを抑制する方法および抗原への免疫応答を増大する方法 Download PDF

Info

Publication number
JP5565906B2
JP5565906B2 JP2010504215A JP2010504215A JP5565906B2 JP 5565906 B2 JP5565906 B2 JP 5565906B2 JP 2010504215 A JP2010504215 A JP 2010504215A JP 2010504215 A JP2010504215 A JP 2010504215A JP 5565906 B2 JP5565906 B2 JP 5565906B2
Authority
JP
Japan
Prior art keywords
tumor
cells
antigen
mice
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010504215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010526034A (ja
JP2010526034A5 (https=
Inventor
ワン，シャン‐ヤン
サブジェック，ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of JP2010526034A publication Critical patent/JP2010526034A/ja
Publication of JP2010526034A5 publication Critical patent/JP2010526034A5/ja
Application granted granted Critical
Publication of JP5565906B2 publication Critical patent/JP5565906B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010504215A 2007-04-16 2008-04-16 スカベンジャー受容体−ａを抑制する方法および抗原への免疫応答を増大する方法 Expired - Fee Related JP5565906B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92362807P 2007-04-16 2007-04-16
US60/923,628 2007-04-16
PCT/US2008/060479 WO2008131006A2 (en) 2007-04-16 2008-04-16 Method for inhibiting scavenger receptor-a and increasing immune response to antigens

Publications (3)

Publication Number Publication Date
JP2010526034A JP2010526034A (ja) 2010-07-29
JP2010526034A5 JP2010526034A5 (https=) 2011-05-19
JP5565906B2 true JP5565906B2 (ja) 2014-08-06

Family

ID=39853929

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010504215A Expired - Fee Related JP5565906B2 (ja) 2007-04-16 2008-04-16 スカベンジャー受容体−ａを抑制する方法および抗原への免疫応答を増大する方法

Country Status (6)

Country Link
US (2) US8133875B2 (https=)
EP (1) EP2147011A4 (https=)
JP (1) JP5565906B2 (https=)
CN (1) CN101675066A (https=)
CA (1) CA2684278C (https=)
WO (1) WO2008131006A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2536432B1 (en) 2010-02-19 2018-08-08 Cornell University Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078145A1 (en) 1999-06-24 2000-12-28 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists
GB9927328D0 (en) * 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
WO2003042246A2 (en) * 2001-11-14 2003-05-22 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
WO2004080385A2 (en) * 2003-03-12 2004-09-23 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating an inflammation

Also Published As

Publication number Publication date
EP2147011A4 (en) 2012-07-18
CN101675066A (zh) 2010-03-17
CA2684278A1 (en) 2008-10-30
US8314076B2 (en) 2012-11-20
US8133875B2 (en) 2012-03-13
EP2147011A2 (en) 2010-01-27
WO2008131006A2 (en) 2008-10-30
CA2684278C (en) 2018-06-12
US20080254072A1 (en) 2008-10-16
JP2010526034A (ja) 2010-07-29
US20120156223A1 (en) 2012-06-21
WO2008131006A3 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
EP2862579B1 (en) Tumor immunity
Motomura et al. Embryonic Stem Cell–Derived Dendritic Cells Expressing Glypican-3, a Recently Identified Oncofetal Antigen, Induce Protective Immunity against Highly Metastatic Mouse Melanoma, B16-F10
JP2011505144A (ja) 樹状細胞ワクチン組成物およびその使用
WO2013063019A1 (en) Methods and compositions for enhancing the therapeutic effect of anti-tumor t cells
US20200062816A1 (en) IL-31 Improves Efficacy of Macrophage-Based Adoptive Cell Therapy for Cancer
CN111050789A (zh) 用于诱导针对肿瘤和癌症的体液免疫和细胞免疫的组合物和方法
Fujii et al. Cancer immunotherapy using artificial adjuvant vector cells to deliver NY‐ESO‐1 antigen to dendritic cells in situ
JP2008521410A (ja) 哺乳動物細胞におけるＩｉ発現の抑制
WO2020214820A2 (en) Aim2 inhibitors and uses thereof
JP2024504924A (ja) 腫瘍及びがんを予防するための組成物及び方法
US9795660B2 (en) Id-protein targeted tumor cell vaccine
JP5565906B2 (ja) スカベンジャー受容体−ａを抑制する方法および抗原への免疫応答を増大する方法
AU2016355586A1 (en) Compositions and methods of treating cancer
Braun et al. In vivo silencing of A20 via TLR9-mediated targeted SiRNA delivery potentiates antitumor immune response
US20140105885A1 (en) Method for Inhibiting Scavenger Receptor-A and Increasing Immune Response to Antigens
Tu et al. Incorporation of a TGF-β2-inhibiting oligodeoxynucleotide molecular adjuvant into a tumor cell lysate vaccine to enhance antiglioma immunity in mice
Le Pogam et al. DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies
US20090060889A1 (en) Ii-RNAi involved Ii suppression in cancer immunotherapy
WO2021048315A1 (en) Use of duox1 inhibitors for treating cancer
HK1140491A (en) Method for inhibiting scavenger receptor-a and increasing immune response to antigens
EP4619509A1 (en) T cell-nk cell interaction inhibitors for use in disease treatment
Cubillos-Ruiz Re-programming tumor-infiltrating dendritic cells in situ via RNAi elicits therapeutic immunity against ovarian cancer
Colombo Reversal of Tumor-induced Dendritic Cell Paralysis by CpG Immunostimulatory Oligonucleotide and Anti-Interleukin 10 Receptor Antibody
Dai An escherichia coli vaccine co-expressing listeriolysin-O and tumour antigen in cancer immunotherapy and the mechanisms of immune regulation
US20100322963A1 (en) Low dose inoculation with tap for anti-tumor immunity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140206

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140611

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140613

R150 Certificate of patent or registration of utility model

Ref document number: 5565906

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees